Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.

ABSTRACT:

Objective

Although most patients diagnosed with early-stage cutaneous melanoma (CM) have excellent outcomes, because of the large number diagnosed each year, many will experience recurrence or death. Prognostic testing for CM using the 31-gene expression profile (31-GEP) test can benefit patients by helping guide risk-appropriate treatment and surveillance plans. We sought to evaluate patients' attitudes toward prognostic testing with the 31-GEP and assess whether patients experience decision regret about having 31-GEP testing.

Methods

A 43-question survey was distributed by the Melanoma Research Foundation in June-August 2021 to CM patients enrolled in their database. Patients were asked questions regarding their decision to undergo 31-GEP testing and the extent to which th

SUBMITTER: Ahmed K 

PROVIDER: S-EPMC9883557 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature